Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 USD | +3.57% | +2.84% | +34.26% |
May. 09 | Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 07 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
Business Summary
Number of employees: 108
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Diagnostic Clinical Services
100.0
%
| 32 | 100.0 % | 40 | 100.0 % | +26.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 32 | 100.0 % | 40 | 100.0 % | +26.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Burnell
CEO | Chief Executive Officer | 62 | 20-11-30 |
Director of Finance/CFO | 32 | 19-05-31 | |
Nicole Massoll
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | - | |
Jody Campbell
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Vijay Aggarwal
BRD | Director/Board Member | 75 | 22-01-31 |
Joseph Keegan
BRD | Director/Board Member | 71 | 15-12-31 |
Stephen Sullivan
BRD | Director/Board Member | 77 | 04-08-31 |
Fortunato Rocca
BRD | Director/Board Member | 62 | 20-01-21 |
Thomas Burnell
CEO | Chief Executive Officer | 62 | 20-11-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 47,000 | 0 | 0 | 72.17 % |
Stock B | 1 | 4,472,442 | 3,227,921 ( 72.17 %) | 96,044 ( 2.147 %) |
Company contact information
Interpace Biosciences, Inc.
Waterview Plaza Suite 310
07054, Parsippany
+855 776 6419
http://www.interpacediagnostics.comSector
1st Jan change | Capi. | |
---|---|---|
+34.26% | 6.34M | |
-8.99% | 5.89B | |
+5.42% | 1.31B |
- Stock Market
- Equities
- IDXG Stock
- Company Interpace Biosciences, Inc.